Simcere Pharmaceutical Group Overview

  • Year Founded
  • 1995

Year Founded

  • Status
  • Public

  • Employees
  • 7,661

Employees

  • Stock Symbol
  • 02096

Stock Symbol

  • Investments
  • 13

  • Share Price
  • $0.87
  • (As of Friday Closing)

Simcere Pharmaceutical Group General Information

Description

Simcere Pharmaceutical Group Ltd is engaged in the R&D, production and commercialization of pharmaceuticals focused on generic pharmaceuticals. It has a diversified product portfolio focused on therapeutic areas, including, oncology (including cell therapy), nervous system diseases, autoimmune diseases and antiinfection. The company's products include Endostar, Enweida, Iremod, Sanbexin and Others.

Contact Information

Website
www.simcere.com
Formerly Known As
Jiangsu Cuccess Pharmaceutical
Ownership Status
Publicly Held
Financing Status
Formerly PE-Backed
Primary Industry
Pharmaceuticals
Stock Exchange
HKG
Primary Office
  • 699-18, Xuanwu Avenue
  • Nanjing, Jiangsu 210042
  • China
+86 025 0000 0000

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Simcere Pharmaceutical Group Stock Performance

(As of Friday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$0.87 $0.88 $0.74 - $1.88 $2.3B 2.62B 4.99M $0.17

Simcere Pharmaceutical Group Financials Summary

In Thousands,
USD
TTM 30-Jun-2023 FY 2022 31-Dec-2022 FY 2021 31-Dec-2021 FY 2020 31-Dec-2020
EV 2,477,937 3,769,344 3,003,103 3,476,577
Revenue 1,006,293 938,311 774,300 652,623
EBITDA 450,656 170,112 256,488 164,273
Net Income 451,995 138,505 233,402 96,913
Total Assets 1,749,377 1,562,639 1,594,130 1,675,020
Total Debt 159,420 218,391 256,645 505,107
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Simcere Pharmaceutical Group Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Simcere Pharmaceutical Group‘s full profile, request access.

Request a free trial

Simcere Pharmaceutical Group Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Simcere Pharmaceutical Group Ltd is engaged in the R&D, production and commercialization of pharmaceuticals focused on g
Pharmaceuticals
Nanjing, China
7,661 As of 2023
00000
0.000 0000-00-00
00000000 00000

000000

on ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolo
000000000000000
Pune, India
0000 As of 0000
00.000
00000000 00.000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Simcere Pharmaceutical Group Competitors (1)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
000000 Private Equity-Backed Pune, India 0000 00.000 00000000 00.000
You’re viewing 1 of 1 competitors. Get the full list »

Simcere Pharmaceutical Group Patents

Simcere Pharmaceutical Group Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
EP-4176868-A4 Stable pharmaceutical composition Pending 17-Aug-2020 000000000 0
EP-4176868-A1 Stable pharmaceutical composition Pending 17-Aug-2020 000000000
AU-2021329765-A1 Stable pharmaceutical composition Pending 17-Aug-2020 000000000
CA-3188671-A1 Stable pharmaceutical composition Pending 17-Aug-2020 000000000
JP-2023539573-A Stable pharmaceutical composition Pending 17-Aug-2020 A61K47/02
To view Simcere Pharmaceutical Group’s complete patent history, request access »

Simcere Pharmaceutical Group Executive Team (11)

Name Title Board Seat Contact Info
Jinsheng Ren Chief Executive Officer & Chairman
Honggang Feng President
Yushan Wan Chief Financial Officer, Finance & Board Member
Frank Zhao Chief Financial Officer
Cheng Zhang Chief Operating Officer and Executive Director
You’re viewing 5 of 11 executive team members. Get the full list »

Simcere Pharmaceutical Group Board Members (3)

Name Representing Role Since
00000000 000 Simcere Pharmaceutical Group Chief Executive Officer & Chairman 000 0000
000000 000 Simcere Pharmaceutical Group Chief Financial Officer, Finance & Board Member 000 0000
You’re viewing 2 of 3 board members. Get the full list »

Simcere Pharmaceutical Group Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Simcere Pharmaceutical Group Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Simcere Pharmaceutical Group‘s full profile, request access.

Request a free trial

Simcere Pharmaceutical Group Investments (13)

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Neurondawn Pharmaceutical 06-Feb-2023 00000 0000 000.00 Drug Discovery
Carmine Therapeutics 29-Nov-2022 00000 0000 000.00 Biotechnology
Neurondawn Pharmaceutical 23-Jul-2022 00000 0000 Drug Discovery
Reju Therapeutics 14-Oct-2021 000000000 Drug Discovery
Neurondawn Pharmaceutical 23-Aug-2021 Early Stage VC 000.00 Drug Discovery
You’re viewing 5 of 13 investments. Get the full list »

Simcere Pharmaceutical Group Subsidiaries (2)

Company Name Industry Location Founded
Simcere Diagnostic Equipment Nanjing, China 2017
Jilin Boda pharmaceutical Pharmaceuticals Liaoyuan, China 0000
To view Simcere Pharmaceutical Group’s complete subsidiaries history, request access »

Simcere Pharmaceutical Group ESG

Risk Overview

Risk Rating

Updated February, 04, 2023

31.33 | High Risk

Risk Scale

A lower score indicates better sustainability

Negl

0-10

Low

10-20

Med

20-30

High

30-40

Severe

40+

Exposure

Exposure refers to the extent to which a company is exposed to different material ESG issues

00.00

Management

Management is related to actions taken to manage ESG issues

00.00

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

00 of 15,708

Rank

00.00

Percentile

Pharmaceuticals

Industry

00 of 884

Rank

00.00

Percentile

Pharmaceuticals

Subindustry

00 of 418

Rank

00.00

Percentile

To view Simcere Pharmaceutical Group’s complete esg history, request access »

Simcere Pharmaceutical Group Exits (3)

Company Name Exit Date Exit Type Exit Size Status Buyers
3D Medicines 23-Dec-2019 00000 00000 00 00000 Completed
  • 6 buyers
I-Mab Biopharma 30-Jun-2016 0000 00000 00.00 Completed
  • 2 buyers
Shanghai Celgen Biopharma 01-Aug-2009 Corporate Completed
To view Simcere Pharmaceutical Group’s complete exits history, request access »